Emerging B-Cell Therapies in Systemic Lupus Erythematosus
| Autor: | Joyce S Hui-Yuen, Ayse Bag-Ozbek |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Review
epratuzumab 030204 cardiovascular system & hematology Ofatumumab Atacicept 03 medical and health sciences chemistry.chemical_compound rituximab 0302 clinical medicine systemic lupus erythematosus Blisibimod immune system diseases medicine Pharmacology (medical) 030212 general & internal medicine General Pharmacology Toxicology and Pharmaceutics skin and connective tissue diseases Chemical Health and Safety treatment business.industry General Medicine medicine.disease Belimumab Tabalumab chemistry Immunology Rituximab Ocrelizumab novel B-cell therapies belimumab business Safety Research Epratuzumab medicine.drug |
| Zdroj: | Therapeutics and Clinical Risk Management |
| ISSN: | 1178-203X |
| Popis: | Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease of unknown etiology, whose hallmark is the production of autoantibodies. B cells are promising targets for novel SLE therapies. In 2011, belimumab (Benlysta®), a fully humanized monoclonal antibody inhibiting B-cell activation and proliferation, was the first medication in 50 years to be approved by the US Food and Drug Administration to treat adult SLE. This review discusses the current experience with B-cell-targeted therapies, including those targeting B-cell-surface antigens (rituximab, ocrelizumab, ofatumumab, obinutuzumab, obexelimab, epratuzumab, daratumumab), B-cell survival factors (belimumab, tabalumab, atacicept, blisibimod), or B-cell intracellular functions (ibrutinib, fenebrutinib, proteasome inhibitors), for the management of SLE. It focuses on ongoing clinical trials and real-world post-marketing use, where available, including their safety profiles, and concludes with our recommendations for B-cell-centric approaches to the management of SLE. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |